News items related to: News
-
TNP+ is Successfully Opposing Big Pharma’s Hepatitis C Drug Monopoly
This win comes after years of campaigning by the AIDS Access Foundation (AAF) and the Thai Network of People Living...
-
Lenacapavir Patent Faces Opposition at the Eurasian Patent Office
“If Gilead Science’s patent application regarding Lenacapavir is granted, the patent will represent another significant barrier to the affordable access...
-
Major Win: First Batch of Dolutegravir Arrives in Colombia Under a Compulsory License
The World Health Organization (WHO) recommends dolutegravir as the first- and second-line treatment for all population groups. In Colombia, access...
-
ITPC-EECA Challenges Patents on core DR-TB Drug Pretomanid, Urging Eurasian Patent Office to Protect Access
According to WHO, 400,000 people developed DR-TB in 2023, yet only 44% (175, 923) of them were treated for it....
-
Ukrainian Patient Rights Group Opposes a Patent Applications on a Life-Saving HIV Drug
Rilpivirine, commonly known as RPV, is available in multiple formulations, including a daily oral medication, and in fixed-dose combination tablets,...
-
Civil Society Groups Unite to Monitor the 4th Round of Thailand-EU FTA Negotiation
Grave concerns over expensive medicines, the universal health coverage scheme at risk, unsafe second-hand medical devices, farmers’ increasing debts &...
-
MMA Partner VNP+ Opposes Patent Application Which Would Limit Access to Long-Acting Cabotegravir
Vietnam’s Network of People Living With HIV (VNP+), a Make Medicines Affordable (MMA) partner, is working to improve access to, and affordability...
-
Thai HIV Advocacy Group Challenges Gilead’s and Janssen’s Patent Extension Bid, Citing Evergreening Tactics
The Thai Network of People Living with HIV/AIDS (TNP+) filed an opposition to a patent application filed by the U.S.-based pharmaceutical giant...
-
Global South Leaders Condemn Gilead’s Restrictive License on HIV Prevention Breakthrough
Civil society organizations across the Global South are blasting the U.S.-based pharmaceutical company Gilead Sciences for its lenacapavir (LEN) voluntary...
-
Indonesian Advocates Challenge Big Pharma’s Patent of HIV Prevention and Treatment Lenacapavir
Indonesia AIDS Coalition (IAC), a community-based organization advocating on HIV-related issues, filed a post-grant opposition against the secondary (selection) patent...
-
Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lenacapavir
New Delhi, 18 September 2024 – The Indian Patent Office is set to hear the objections of Sankalp Rehabilitation Trust...
-
HIV Community-Based Organizations are Fighting Patent Monopolies on Lenacapavir
Despite the world’s efforts, there have been over a million new cases of HIV each year. Lenacapavir (LEN), a long-acting...
